Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research.
Int J Clin Oncol
; 26(2): 335-344, 2021 Feb.
Article
in English
| MEDLINE | ID: covidwho-882390
ABSTRACT
Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of emergency was declared in Japan, as had been by other nations worldwide. This unprecedented crisis has profound implications for patients undergoing chemotherapy and for practicing healthcare professionals. Various reports have shown data indicating that cancer patients with COVID-19 have high morbidity and mortality rates. In order to reduce the use of medical resources to avoid the risk of COVID-19 infections in both cancer patients and health care providers, oncologists now have to draw the line for cancer treatments by maintaining their efficacy while avoiding severe adverse events. In this article, we outlined the decisions made regarding the practice of gastrointestinal oncology in our institution during the COVID pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cancer Care Facilities
/
Oncologists
/
Gastrointestinal Neoplasms
/
COVID-19
/
Medical Oncology
/
Antineoplastic Agents
Type of study:
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Int J Clin Oncol
Journal subject:
Neoplasms
Year:
2021
Document Type:
Article
Affiliation country:
S10147-020-01806-7
Similar
MEDLINE
...
LILACS
LIS